Search for: "Boehringer Ingelheim, Inc."
Results 81 - 100
of 155
Sorted by Relevance
|
Sort by Date
9 Dec 2010, 3:53 am
" Specifically, "Boehringer Ingelheim GmbH's Roxane Inc. will pay $280 million, Abbott will pay $126.5 million and B. [read post]
22 May 2009, 5:00 am
This is the opening sentence of the England and Wales High Court's decision on an interim injunction in Interflora, Inc. [read post]
10 Mar 2010, 5:22 am
(FDA Law Blog) US: Review and correction of patent term adjustment calculation made by the USPTO: Boehringer Ingelheim Pharma GmbH & Co. [read post]
10 Mar 2010, 5:22 am
(FDA Law Blog) US: Review and correction of patent term adjustment calculation made by the USPTO: Boehringer Ingelheim Pharma GmbH & Co. [read post]
9 Jun 2011, 12:43 pm
But Lilly recently struck a deal to promote a rival diabetes drug, Tradjenta, with Germany’s Boehringer Ingelheim using the same sales force. [read post]
14 Oct 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb) Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no… [read post]
16 Mar 2015, 9:23 am
., Pfizer Inc., and Boehringer Ingelheim GmbH all have similar medications currently in development. [read post]
29 Dec 2009, 9:09 pm
Director Team Leader, International Business Development, Pfizer Bill Bertrand, Senior Vice President, Legal Affairs, General Counsel and Corporate Compliance Officer, MedImmune Adelene Perkins, President and Chief Business Officer, Infinity Pharmaceuticals Michael Leonetti; Head, Health Care Partnerships, Boehringer Ingelheim David Low, Managing Director, Lazard Sanj Singh, CEO, Ade Therapuetics Here is a link to the event where you can get more… [read post]
29 Dec 2009, 9:09 pm
Director Team Leader, International Business Development, Pfizer Bill Bertrand, Senior Vice President, Legal Affairs, General Counsel and Corporate Compliance Officer, MedImmune Adelene Perkins, President and Chief Business Officer, Infinity Pharmaceuticals Michael Leonetti; Head, Health Care Partnerships, Boehringer Ingelheim David Low, Managing Director, Lazard Sanj Singh, CEO, Ade Therapuetics Here is a link to the event where you can get more… [read post]
1 Apr 2012, 11:22 am
Eliquis, from Bristol-Myers Squibb Co and Pfizer Inc, would be the third new U.S. treatment for these patients after Xarelto, from Bayer and Johnson & Johnson, was approved, and Pradaxa from Boehringer Ingelheim. [read post]
9 Feb 2011, 2:51 pm
Litig., MDL No. 2211 In re Student-Athlete Name & Likeness Litig., MDL No. 2212 In re Crystal Poole IRS Summons Litig., MDL No. 2216 In re Boehringer Ingelheim Pharm., Inc., Fair Labor Standards Act (FLSA) Litig., MDL No. 2219 Blawgletter wonders whether the fact that the Panel rejected motions to centralize cases in fully half of the MDL matters -- nine out of 18 -- made for quicker decisions. [read post]
9 Nov 2020, 3:00 am
Currently, the defendants in active Zantac cancer injury cases include: Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
9 Nov 2020, 3:00 am
Currently, the defendants in active Zantac cancer injury cases include: Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
9 Nov 2020, 3:00 am
Currently, the defendants in active Zantac cancer injury cases include: Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
18 Mar 2010, 2:30 am
Amgen, Inc. [read post]
9 Mar 2015, 2:38 pm
Litigation and Government Investigations at Boehringer Ingelheim Pharmaceuticals where she oversaw all U.S. litigation and government investigations. [read post]
30 Dec 2009, 3:44 am
In this event Panels partially dismiss complaints to the extent that they include additional unrelated respondents, as in Boehringer Ingelheim Pharma GmbH & Co. [read post]
11 Jan 2024, 12:03 am
The FIE determination released in fall 2023 involves the Reference Product AbbVie’s Humira (adalimumab) and two interchangeable biosimilars—first approved is Cyltezo (adalimumab-adbm), filed by Boehringer Ingelheim Pharmaceuticals, Inc, which was followed by Abrilada (adalimumab-afzb), filed by Pfizer. [read post]
1 Aug 2019, 8:30 am
Boehringer Ingelheim Corp., et al., a $150 million settlement with GlaxoSmithKline PLC, and a $190 million settlement with Aventis Pharmaceuticals, Inc. [read post]
6 Nov 2007, 5:55 am
Rosenbaum, District of MinnesotaNature of Suits: Consists of 58 actions against Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. arising from use of Mirapex, a treatment for Parkinson's disease, which alleged causes obsessive pleasure- and reward-seeking behavior, such as gambling.In re Kugel Mesh Hernia Patch Products Liability Litigation, MDL 1842Filed 2/28/07 and ordered to be transferred on 6/22/2007Transferee Judge and Court: Mary H. [read post]
